KADCYLA 160 mg Powder for Concentrate for Solution for Infusion

KADCYLA (trastuzumab emtansine) is an advanced targeted therapy used in the treatment of specific types of breast cancer.
This innovative medication combines the power of HER2-targeted therapy with a potent chemotherapy agent, delivering treatment directly to cancer cells.
By minimizing exposure to healthy cells, KADCYLA aims to enhance efficacy while reducing systemic side effects.
It is a crucial option for patients with HER2-positive breast cancer, offering a specialized approach to combat the disease.
For further details and availability, please refer to reputable pharmaceutical retailers such as Nahdi Online, , or .

Benefits of Use

• Targets HER2-positive breast cancer cells specifically, delivering chemotherapy directly to the tumor.
• Approved for the treatment of HER2-positive metastatic breast cancer after prior therapy.
• Also indicated for HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment.
• Offers a dual mechanism of action, combining an antibody with an anti-microtubule agent.
• Designed to improve progression-free survival and overall survival in eligible patients.

How to Use

KADCYLA is an intravenous medication that must be administered by a qualified healthcare professional.

1. KADCYLA is supplied as a powder for concentrate, which will be reconstituted and diluted by a pharmacist or nurse.
2. The medication is administered via intravenous infusion in a clinical setting (hospital or infusion center).
3. Dosage and frequency of administration are determined by your physician based on your specific medical condition, weight, and response to treatment.
4. Each infusion typically takes 30 to 90 minutes, with patients closely monitored during and after the administration for any reactions.
5. It is crucial to adhere strictly to the schedule prescribed by your healthcare provider for optimal therapeutic benefit.

Caution & Warnings

• Hepatotoxicity: KADCYLA can cause severe, life-threatening liver damage. Liver function should be monitored regularly.
• Cardiac Toxicity: May cause left ventricular dysfunction and heart failure. Cardiac function (e.g., LVEF) should be assessed before and during treatment.
• Pulmonary Toxicity: Interstitial lung disease and pneumonitis, some fatal, have been reported. Monitor for signs of lung complications.
• Hemorrhage: Serious bleeding events, including cerebral hemorrhage, have occurred. Monitor for signs of hemorrhage.
• Thrombocytopenia: Can cause decreased platelet counts. Complete blood counts should be monitored prior to each dose.
• Embryo-Fetal Toxicity: May cause fetal harm when administered to a pregnant woman. Advise women of reproductive potential to use effective contraception.
• Infusion-Related Reactions: Serious infusion-related reactions, including anaphylaxis, can occur. Monitor patients during and after infusion.
• Not for Self-Administration: KADCYLA must be administered by a healthcare professional experienced in oncology care.

Ingredients

• Active Ingredient: Trastuzumab Emtansine (160 mg per vial).
• Excipients: Sucrose, L-Histidine, L-Histidine Monohydrochloride Monohydrate, Polysorbate 20.

Product Details

• Product Name: KADCYLA 160 mg Powder for Concentrate for Solution for Infusion.
• Strength: 160 mg.
• Dosage Form: Powder for concentrate for solution for infusion.
• Manufacturer: Roche.
• Packaging: Single-use vial.
• Type: Targeted Antibody-Drug Conjugate (ADC) for HER2-positive cancer.